Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Fish and Richardson
Citi
Accenture
Boehringer Ingelheim
Mallinckrodt
Covington
Merck

Generated: November 14, 2018

DrugPatentWatch Database Preview

Perrigo Company Profile

« Back to Dashboard

What is the competitive landscape for PERRIGO, and what generic alternatives to PERRIGO drugs are available?

PERRIGO has two hundred and fourteen approved drugs.

There are four US patents protecting PERRIGO drugs. There is one tentative approval on PERRIGO drugs.

Drugs and US Patents for Perrigo

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Israel FLUTICASONE PROPIONATE fluticasone propionate LOTION;TOPICAL 091553-001 Jul 30, 2013 AB RX No No ➤ Sign Up ➤ Sign Up
Perrigo Pharma Intl ENTOCORT EC budesonide CAPSULE;ORAL 021324-001 Oct 2, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Perrigo LORATADINE loratadine TABLET;ORAL 021512-001 Jun 24, 2004 DISCN No No ➤ Sign Up ➤ Sign Up
Perrigo New York TRIAMCINOLONE ACETONIDE triamcinolone acetonide OINTMENT;TOPICAL 087385-003 Approved Prior to Jan 1, 1982 AT RX No Yes ➤ Sign Up ➤ Sign Up
Perrigo Israel HALOBETASOL PROPIONATE halobetasol propionate CREAM;TOPICAL 077123-001 Dec 16, 2004 AB RX No No ➤ Sign Up ➤ Sign Up
Perrigo ACETAMINOPHEN, ASPIRIN AND CAFFEINE acetaminophen; aspirin; caffeine TABLET;ORAL 075794-001 Nov 26, 2001 OTC No No ➤ Sign Up ➤ Sign Up
Perrigo Uk Finco BETAMETHASONE VALERATE betamethasone valerate AEROSOL, FOAM;TOPICAL 078337-001 Nov 26, 2012 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Perrigo

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl BUTOCONAZOLE NITRATE butoconazole nitrate CREAM;VAGINAL 019881-001 Feb 7, 1997 4,551,148 ➤ Sign Up
Perrigo New York CENTANY mupirocin OINTMENT;TOPICAL 050788-001 Dec 4, 2002 6,013,657 ➤ Sign Up
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 6,923,983 ➤ Sign Up
Perrigo Pharma Intl CLINDESSE clindamycin phosphate CREAM;VAGINAL 050793-001 Nov 30, 2004 5,266,329 ➤ Sign Up
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 6,299,900 ➤ Sign Up
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 6,818,226 ➤ Sign Up
Perrigo Pharma Intl BUTOCONAZOLE NITRATE butoconazole nitrate CREAM;VAGINAL 019881-001 Feb 7, 1997 4,078,071 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for PERRIGO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Enteric Coated Capsules 3 mg ➤ Subscribe 2008-02-01
➤ Subscribe Vaginal Cream 2% ➤ Subscribe 2009-12-23
➤ Subscribe Vaginal Cream 2% ➤ Subscribe 2015-02-05

Supplementary Protection Certificates for Perrigo Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0040 France ➤ Sign Up PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
00043 Netherlands ➤ Sign Up PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
C/GB08/018 United Kingdom ➤ Sign Up PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
C0014 France ➤ Sign Up PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
C/GB05/030 United Kingdom ➤ Sign Up PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
/1999 Austria ➤ Sign Up PRODUCT NAME: MONTELUKAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MONTELUKASTNATRIUM; NAT. REGISTRATION NO/DATE: 1-22765 UND 1-22766 19981030; FIRST REGISTRATION: FI 12766 UND 12767 19970825
2008000041 Germany ➤ Sign Up PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chubb
AstraZeneca
Citi
Healthtrust
Cipla
Harvard Business School
UBS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.